Novel Therapeutics Clinic advances innovations in treating cancer and the side effects of cancer treatment.
New research aims to determine whether differences in the blood-based proteome between men and women with Alzheimer’s can help identify biomarkers to improve care for women with the disease.
Researchers are analyzing gene expression signatures to better predict which therapy will work best for each patient with cancer.
Although anti-VEGF therapy is the current gold-standard treatment for retinal vein occlusion, not all patients respond to it. A study has found that volume of intraretinal fluid, among other factors detectable with optical coherence tomography, may help predict treatment response.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Understanding the molecular features of DLBLC tumors may aid in improving treatment efficacy.
We explain why we’ve launched an Epilepsy Precision Medicine Fellowship and how it’s designed to empower tomorrow’s epileptologists to apply neurogenetics to improve patient care
A paradigm shift is needed in inflammatory bowel disease, a Cleveland Clinic researcher contends, moving from reactive, symptom-based treatment to predictive biomarkers that forecast disease course and enable personalized, targeted therapies to prevent additional tissue damage.
Cleveland Clinic teams with PDGx to harness the diagnostic power of liquid biopsy and increase the use of precision diagnostics within the cancer care continuum.
A group of researchers led by Jacob Scott, MD, DPhil, have validated a quantifiable, genomically guided parameter that serves as a predictor of the therapeutic benefit of RT for each individual patient.
Most therapies in development for Alzheimer’s are focused on changing disease biology, with targets ranging from amyloid pathology to inflammation. A leader of our clinical trials program shares an update on drug development and diagnostics.